Abstract | AIMS: METHODS AND RESULTS: Overall, 2,603 patients were randomised to treatment with the Yukon Choice PC (n=1,299), XIENCE (n=652) or CYPHER (n=652) stents. The primary endpoint was the device-oriented composite of cardiac death, target vessel-related myocardial infarction (MI), or target lesion revascularisation (TLR). The main secondary endpoint was definite/probable stent thrombosis (ST). Follow-up was performed up to five years. Concerning the primary endpoint, there was no significant difference between Yukon Choice PC and XIENCE stents (20.5% vs. 19.5%, HR=1.04, 95% CI: 0.84-1.29; p=0.71) or between CYPHER and XIENCE stents (23.5% vs. 19.5%, HR=1.21, 95% CI: 0.95-1.53; p=0.12). In terms of safety, rates of ST were similar with both Yukon Choice PC and XIENCE (1.2% vs. 1.4%; HR=0.83, 95% CI: 0.37-1.91; p=0.67) but numerically higher with CYPHER as compared to XIENCE (2.4% vs. 1.4%, HR=1.67, 95% CI: 0.73-3.82; p=0.22). CONCLUSIONS: Biodegradable polymer Yukon Choice PC and permanent polymer XIENCE stents showed comparable clinical outcomes at five years. Permanent polymer CYPHER stents showed numerically higher rates of device-related adverse events. Trials registration: ClinicalTrials.gov (identifier: NCT00598676).
|
Authors | Sebastian Kufner, Robert A Byrne, Marco Valeskini, Stefanie Schulz, Tareq Ibrahim, Petra Hoppmann, Simon Schneider, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati, Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST4) Investigators |
Journal | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
(EuroIntervention)
Vol. 11
Issue 12
Pg. 1372-9
(Mar 2016)
ISSN: 1969-6213 [Electronic] France |
PMID | 25405657
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Cardiovascular Agents
- Coated Materials, Biocompatible
- Polymers
- Everolimus
- Sirolimus
|
Topics |
- Absorbable Implants
- Aged
- Cardiovascular Agents
(administration & dosage, adverse effects)
- Coated Materials, Biocompatible
- Coronary Artery Disease
(diagnostic imaging, mortality, therapy)
- Coronary Thrombosis
(etiology)
- Drug-Eluting Stents
- Everolimus
(administration & dosage, adverse effects)
- Female
- Germany
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Percutaneous Coronary Intervention
(adverse effects, instrumentation, mortality)
- Polymers
(chemistry)
- Proportional Hazards Models
- Prosthesis Design
- Risk Factors
- Sirolimus
(administration & dosage, adverse effects)
- Time Factors
- Treatment Outcome
|